Akimoto, Naohiko
Ugai, Tomotaka
Zhong, Rong
Hamada, Tsuyoshi
Fujiyoshi, Kenji
Giannakis, Marios
Wu, Kana
Cao, Yin
Ng, Kimmie
Ogino, Shuji http://orcid.org/0000-0002-3909-2323
Article History
Accepted: 14 October 2020
First Online: 20 November 2020
Competing interests
: K.N. has received institutional research funding from Evergrande Group, Genentech, Gilead Sciences, Pharmavite, Revolution Medicines, Tarrex Biopharma and Trovagene, and has served on advisory boards for Array Biopharma, Bayer and Seattle Genetics. M.G. has received research funding from Bristol-Myers Squibb and Merck. The other authors declare no competing interests.